Phase I trial of combined chemotherapy of bevacizumab, panitumumab and irinotecan as 3rd-line chemotherapy in chmotherapy-refractory metastatic colorectal cancer.
Phase 1
- Conditions
- Colorectal cancer
- Registration Number
- JPRN-UMIN000009362
- Lead Sponsor
- ational Cancer Center Hospital, Tokyo, Japan.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
1) Double advenced cancer 2) Past history of severe allergy of drugs 3) Active infection 4) Severe complication such as paresis of intestine, ileus, intestinal pneumonia, uncontrollable DM, cardiac disease, uncontrolled hypertension, thrombosis, renal failure, liver failure 5) Previous use of anti-EGFR antibodies 6) Uncontorollable pleural effusion and acites 7) Asymptomatic brain metastasis 8) Active bleeding of intestine 9) Uncontrollable diarrhea 10) Female with pregnancy 11) Inappropriate patients for clinical trial that are judged by doctors
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method